This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== ADLM Members == ADLM's approximately 8,000 members come from all areas of lab medicine—clinical and research laboratories, diagnostic companies, government agencies, original equipment manufacturers, and more. Collectively they develop and run lab tests and lab instruments used throughout healthcare. They also manage labs, conduct research involving biomarkers, and promote accurate diagnostic testing. ADLM represents the diverse interests of a global lab community: its members come from 110 countries and hold the spectrum of lab-related professional degrees, certifications, and credentials.
Importantly, the NPYS group can replace the Acm PG to yield an activated thiol. Using this method, Kiso and coworkers reported the first total synthesis of insulin in 1993. In this work, the A-chain of insulin was prepared with following protecting groups in place on its cysteines: CysA6(But), CysA7(Acm), and CysA11(But), leaving CysA20 unprotected.
=== Comparison of effects of brimonidine and timolol === A 2013 Cochrane systematic review compared the effect of brimonidine and timolol in slowing the progression of open-angle glaucoma in adult participants. The results showed that participants assigned to brimonidine showed less visual field progression than those assigned to timolol, though the results were not significant, given the heavy loss-to-followup and limited evidence. The mean intraocular pressures for both groups were similar. Participants in the brimonidine group had a higher occurrence of side effects caused by medication than participants in the timolol group.
S2F10 + Cl2 → 2 SF5Cl The analogous reaction with bromine is reversible and yields SF5Br. The reversibility of this reaction can be used to synthesize S2F10 from SF5Br. It reacts with SO2 to form pentafluorosulfur fluorosulfonate (SF5OSO2F) in the presence of ultraviolet radiation. Ammonia is oxidised by S2F10 into NSF3.
== BOLD-100 derivatives == BOLD-100 is sodium trans-[tetrachlorobis (1H-indazole) ruthenate(III)] with cesium as an intermediate salt form. BOLD-100 was developed from KP1339 (also known as IT-139 or NKP-1339) which is also sodium trans-[tetrachlorobis (1H-indazole) ruthenate(III)], but has different manufacturing methods and purity profiles. The names are often used interchangeably. The precursor to BOLD-100 is KP1019, which is the indazole salt equivalent. KP1019 previously entered Phase 1 clinical trials but development was halted due to low solubility in water, leading to the development of KP1339 and BOLD-100 which are readily soluble in water. KP1019 and KP1339 were invented by Dr. Keppler at the University of Vienna.
Sources: en.wikipedia.org
== Further reading == Huang, T. C.; Teng, D. F. (2004). "Soy Sauce". Handbook of Food and Beverage Fermentation Technology. doi:10.1201/9780203913550.ch29 (inactive 12 July 2025). ISBN 978-0-8247-4780-0.{{cite book}}: CS1 maint: DOI inactive as of July 2025 (link)—on the production of soy sauce
== Contributions to yachting == In retirement John Knox pursued his lifelong interest in yachting, applying scientific rigour to the field of anchoring. He invented the Anchorwatch, a strain gauge which measures the force on an anchor chain, in order to alert crew when their anchor is at risk of slipping during a stormy night. Knox used the Anchorwatch device to establish a testing procedure for measuring an anchor's holding force, and conducted years of experiments on Scotland's beaches to measure the efficiency of most anchor designs available on the global market. His work on anchor testing culminated in the design of his own optimised Knox Anchor, now commercially manufactured in the UK.
== Mythology == Practically all Quechuas in the Andes have been nominally Catholic since colonial times. Nevertheless, traditional religious forms persist in many regions, blended with Christian elements – a fully integrated syncretism. Quechua ethnic groups also share traditional religions with other Andean peoples, particularly belief in Mother Earth (Pachamama), who grants fertility and to whom burnt offerings and libations are regularly made. Also important are the mountain spirits (apu) as well as lesser local deities (wak'a), who are still venerated especially in southern Peru. The Quechuas came to terms with their repeated historical experience of tragedy in the form of various myths. These include the figure of Nak'aq or Pishtaco ("butcher"), the white murderer who sucks out the fat from the bodies of the Indigenous peoples he kills, and a song about a bloody river. In their myth of Wiraquchapampa, the Q'ero people describe the victory of the Apus over the Spaniards. Of the myths still alive today, the Inkarrí myth common in southern Peru is especially interesting; it forms a cultural element linking the Quechua groups throughout the region from Ayacucho to Cusco. Some Quechuas consider classic products of the region such as corn beer, chicha, coca leaves, and local potatoes as having a religious significance, but this belief is not uniform across communities.
=== Diversity and inclusion campaigns === Cave's ethnic origins have been the subject of debate. She has been featured in Diversity Campaigns by MTV, ABC's Good Morning America, SXSW, 100 Top Women in the World List, The Why Culture, and The Color of STEM.
== Charges == On October 20, 2017, a week after the prison attack, the four prisoners – 28-year-old Mikel Brady, 29-year-old Wisezah Buckman, 30-year-old Jonathan Monk and 33-year-old Seth Frazier – were charged with murder for the killings they committed throughout the attack. In June 2018, it was confirmed that all the four accused would undergo separate trials for the 2017 prison murders. On October 13, 2018, District Attorney Andrew Womble confirmed that he would seek the death penalty for all the four inmates. Under North Carolina state law, the death penalty was the maximum sentence for first degree murder.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.